SCHEMBL3377398

SCHEMBL3377398

CS(=O)(=O)Nc1ccc(-c2cc(C(F)(F)F)ccc2F)c(Cl)c1

nearest known ligand 0.51

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 5/20 0.51
NR1H4 Q96RI1 5/20 0.51
KIF11 P52732 4/20 0.50
GAA P10253 1/20 0.44
HPGD P15428 1/20 0.44
MAPK1 P28482 1/20 0.44
CYP17A1 P05093 2/20 0.43
IDH1 O75874 1/20 0.43
PTGDR2 Q9Y5Y4 1/20 0.42
SLC6A2 P23975 2/20 0.41
SLC6A4 P31645 2/20 0.41
SLC6A3 Q01959 2/20 0.41
TRPV1 Q8NER1 1/20 0.41
PPARG P37231 1/20 0.41
SCN5A Q14524 1/20 0.41
SCN9A Q15858 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3375971 0.83 KIF11 (0.66) EPHX2NR1H4KIF11GAAHPGD
SCHEMBL3375693 0.80 KIF11 (0.54) EPHX2NR1H4KIF11GAAHPGD
SCHEMBL4661074 0.80 KIF11 (0.66) EPHX2NR1H4KIF11SCN5ASCN9A
SCHEMBL3379958 0.80 GAA (0.49) KIF11GAAHPGDMAPK1CYP17A1
SCHEMBL3375688 0.80 KIF11 (0.56) EPHX2NR1H4KIF11GAAHPGD
SCHEMBL13366542 0.79 IL2 (0.41) KIF11TRPV1
SCHEMBL3378774 0.79 KIF11 (0.55) EPHX2NR1H4KIF11GAAHPGD
SCHEMBL3375774 0.78 GAA (0.52) KIF11GAAHPGDMAPK1CYP17A1
SCHEMBL11233219 0.77 MEN1 (0.55) KIF11GAAHPGDMAPK1IDH1
SCHEMBL3377007 0.77 KIT (0.51) KIF11GAAHPGDMAPK1CYP17A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8389500-B2 Fused heterocyclic compounds as ion channel modulators GILEAD SCIENCES, INC. (US) 2013-03-05 US claimed
US-20100113449-A1 FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS GILEAD PALO ALTO, INC. (US) 2010-05-06 US claimed
US-8389500-B2 Fused heterocyclic compounds as ion channel modulators GILEAD SCIENCES, INC. (US) 2013-03-05 US disclosed
US-8389500-B2 Fused heterocyclic compounds as ion channel modulators GILEAD SCIENCES, INC. (US) 2013-03-05 US disclosed
US-8389500-B2 Fused heterocyclic compounds as ion channel modulators GILEAD SCIENCES, INC. (US) 2013-03-05 US disclosed
US-20100113449-A1 FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS GILEAD PALO ALTO, INC. (US) 2010-05-06 US disclosed
US-20100113449-A1 FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS GILEAD PALO ALTO, INC. (US) 2010-05-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100113449-A1 FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS KCNJ2, HCN4, KCNH2 EPHX2 1898/4885NR1H4 2215/4885KIF11 3561/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.